NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Nicholas Investment Partners LP

Nicholas Investment Partners LP lifted its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 20.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 213,419 shares of the company’s stock after purchasing an additional 35,881 shares during the period. Nicholas Investment Partners LP’s holdings in NewAmsterdam Pharma were worth $7,487,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. First Turn Management LLC lifted its position in shares of NewAmsterdam Pharma by 24.6% during the fourth quarter. First Turn Management LLC now owns 893,473 shares of the company’s stock worth $31,343,000 after purchasing an additional 176,502 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its position in shares of NewAmsterdam Pharma by 1.4% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 16,943,774 shares of the company’s stock worth $594,388,000 after purchasing an additional 241,818 shares in the last quarter. Kennedy Capital Management LLC lifted its position in shares of NewAmsterdam Pharma by 17.9% during the fourth quarter. Kennedy Capital Management LLC now owns 172,931 shares of the company’s stock worth $6,066,000 after purchasing an additional 26,216 shares in the last quarter. Maverick Capital Ltd. lifted its position in shares of NewAmsterdam Pharma by 25.9% during the fourth quarter. Maverick Capital Ltd. now owns 1,894,226 shares of the company’s stock worth $66,449,000 after purchasing an additional 389,479 shares in the last quarter. Finally, Walleye Capital LLC acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter worth $3,377,000. 89.89% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on NAMS. HC Wainwright raised shares of NewAmsterdam Pharma to a “strong-buy” rating in a report on Thursday, February 19th. Truist Financial began coverage on shares of NewAmsterdam Pharma in a report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 price target on the stock. Guggenheim upped their price target on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Tuesday, April 21st. Finally, Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $48.60.

NewAmsterdam Pharma Price Performance

NAMS stock opened at $30.40 on Friday. NewAmsterdam Pharma Company N.V. has a 1-year low of $17.63 and a 1-year high of $42.21. The firm has a fifty day moving average price of $33.44 and a two-hundred day moving average price of $33.69. The firm has a market cap of $3.55 billion, a price-to-earnings ratio of -16.98 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The business had revenue of $3.04 million for the quarter. As a group, analysts expect that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Louise Frederika Kooij sold 65,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $35.69, for a total transaction of $2,319,850.00. Following the completion of the transaction, the chief accounting officer owned 24,353 shares in the company, valued at approximately $869,158.57. This represents a 72.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 12.74% of the stock is currently owned by insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.